Mark Pavao

Director/Board Member at COYA THERAPEUTICS, INC.

62 year

Health Technology

Profile

Mark H.
Pavao was the founder of R-Pharm US LLC, founded in 2014, where the titles held included President, Chief Executive Officer & Director.
Current jobs include Independent Director at Coya Therapeutics, Inc. starting in 2026, and Chief Commercial Officer at BioXcel Therapeutics, Inc. starting in 2026.
Former job includes Senior Vice President-Sales & Marketing at NitroMed, Inc.

Mark Pavao active positions

Companies	Position	Start
BIOXCEL THERAPEUTICS, INC.	Corporate Officer/Principal	11/01/2026
COYA THERAPEUTICS, INC.	Director/Board Member	31/03/2026

All active positions of Mark Pavao

Former positions of Mark Pavao

Companies	Position	End
R-Pharm US LLC R-Pharm US LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of medicines to treat cancer	Founder	-
NitroMed, Inc. NitroMed, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies pharmaceuticals	Sales & Marketing	-

See the detail of Mark Pavao's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark Pavao's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
NitroMed, Inc. NitroMed, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies pharmaceuticals	Health Technology
R-Pharm US LLC R-Pharm US LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of medicines to treat cancer	Health Technology
BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops transformative medicines in neuroscience and immuno-oncology	Health Technology
Coya Therapeutics, Inc. Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells	Health Technology

See company connections